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STRONGYLOSES RATTI AND S. STERCORALIS: EFFECTS OF CAMBENDAZOLE, 
THIABENDAZOLE AND MEBENDAZOLE IN VITRO 
David I. GROVE and Carolyn NORTHERN 
S U M M A R Y 
The effects of in vitro incubation of three henzimidazole anthelmintics, thia­
bendazole, mebendazole and cambendazole on Strongyloides were compared. No 
drug affected hatching of S. ratti eggs or the viability of infective larvae or para­
sitic adult worms, but all three inhibited moulting of S. ratti larvae. In addition, 
cambendazole, but not thiabendazole or mebendazole, impaired the viability of S. 
ratti first- and second-stage larvae. The three drugs had no effect on isolated S. 
stercorais free-living adult worms, but they all prevented development of S. ster¬ 
coralis rhabditiform larvae. Thiabendazole and mebendazole had no effect on the 
infectivity of either S. ratti or S. stercoralis infective larvae, but infection with 
these worms was abrogated by prior incubation with cambendazole. These results 
indicate that cambendazole acts in a different manner to the other two drugs. 
Since it is active against larvae migrating through the tissues, it is potentially of 
much greater value than thiabendazole or mebendazole in the therapy of stron¬ 
gyloidiasis. 
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I N T R O D U C T I O N 
Strongyloidiasis is one of the major human 
intestinal nematode infections. It is resistant 
to most anthelmintics and thiabendazole has 
been the mainstay of therapy for many years. 
Unfortunately, this drug is not always effective, 
both in uncomplicated strongyloidiasis8 and in 
overwhelming infections in immunosuppressed 
patients " , 2 1 . " A More recently, two related ben-
zimidazole compounds, mebendazole *-17,20 and 
cambendazole 1,3,13,19,23 have been used with va-
variable success. 
Initial studies of the modes of actions of 
benzimidazoles in strongyloidiasis simply asses­
sed the effects of drugs on the excretions of pa­
rasites in the feces of humans and animals in­
fected with various Strongyloides species. It 
was then shown in experimental studies of mice 
with S. ratti infections, that thiabendazole had 
no effect on migratory larvae and did not kill 
adult worms in the gastrointestinal tract, but 
did reduce the fecundity of these worms9. In 
contrast, mebendazole and cambendazole were 
active against both migratory larvae and adult 
worms in the gut. Furthermore, cambendazole 
but not mebendazole eradicated S. stercoralis 
larvae from the muscles of mice. 
Since Strongyloides species complete part 
of their life cycle in the external environment, 
in vitro studies provide an alternative means 
for both screening of drugs for anti-Strongyloi-
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des activity6 and for gaining insight into the 
anthelmintic mechanisms of those drugs. In 
this paper, the effects in vitro of three benzi-
midazole compounds, thiabendazole, mebenda­
zole and cambendazole on S. ratti and S. ster-
coralis have been compared. A homogonic 
strain of S. ratti was us.ed in which eggs hatch­
ed and rhabditiform larvae developed directly 
into infective larvae after two moults. S. ster-
coralis, however, "was heterogonic with rhabdi­
tiform larvae moulting four times to produce 
free-living adult male or female worms which 
in turn produced rhabditiform larvae which 
moulted twice to become infective larvae. 
METHODS 
The source and maintenance of S. ratti by 
Sprague-Dawley rats have been described else­
where s . S. stercoralis was obtained originally 
from infected humans7 and has since been 
maintained in dogs The supply and prepara­
tion of thiabendazole, mebendazole and camben­
dazole have been detailed elsewhere9. 
Feces were collected from infected rats or 
dogs, homogenized in water and the intensity 
of infection quantified. Aliquots were mixed 
with suspensions of thiabendazole or meben­
dazole prepared in 0.1M phosphate buffered 
saline, pH 7.4 (PBS) or a solution of camben­
dazole and placed on watch glasses at room 
temperature. In order to prepare infective lar­
vae, moistened infected feces were placed on 
watch glasses in petri dishes containing a thin 
layer of water; larvae migrated into the water 
and were recovered several days later for S. 
ratti and 10 days later for S. stercoralis. 
The methods for infection of mice with in­
fective larvae and quantification of eggs in the 
feces have been described earlier5. Female pa­
rasitic adult worms of S. ratti were recovered 
from rats by removal of the intestines seven 
days after infection. The intestines were slit 
longitudinally, cut in segments 2 cm long and 
incubated for one hour at 37°C in PBS in a pe­
tri dish; the adult worms were then picked out 
individually with a pipette. The technique for 
quantification of S. stercoralis larvae in the 
muscles of mice has been described in detail 
elsewhere9. Viability of worms was assessed 
on the basis of the morphology of intestinal 
structures and motility of the worms. 
RESULTS 
Effect on hatching of S. ratti eggs 
Thirty-two small watch glasses were each 
set up with 100 jig aliquots of feces containing 
eggs. To each of these was added 400 pi PBS 
containing either no drug or 200 pg of thiaben­
dazole, mebendazole or cambendazole giving a 
final concentration of 400 pg drug/ml. Eight 
dishes were in each group. The numbers of 
viable rhabditiform larvae were counted two 
hours after incubation. Each anthelmintic had 
no effect on hatching of eggs for there were 
no significant differences with any of the treat­
ment groups when compared with the controls 
(Table I ) . 
Effect on viability of first-stage S. ratti larvae 
The same protocol as above was adopted 
except that the numbers of viable rhabditiform 
larvae were counted seven and 24 hours after 
incubation. Thiabendazole and mebendazole had 
no toxic effect on first-stage larvae but there 
was a significant (P < 0.02 "t" test) 52% re­
duction in the numbers of first-stage larvae in 
feces incubated with cambendazole for seven 
hours (Table I ) . 
Effect on first moul of S. ratti 
The same protocol as above was adopted 
except that the numbers of viable first — and 
second-stage larvae were counted 24 hours after 
incubation. At this time, 91;% of larvae in the 
control feces had moulted. There was a highly 
significant reduction (P < 0.001, "t" test) in 
the numbers of second-stage larvae in feces 
treated with any of the anthelmintics, none 
being found in feces incubated with mebenda­
zole or cambendazole and very few in that in­
cubated with thiabendazole (Table I ) . At this 
time, there were large numbers of persistent, 
viable, rhabditiform larvae in feces incubated 
with thiabendazole or mebendazole. When the 
experiment was repeated after 31 hours of in­
cubation similar results were obtained except 
that very few viable first-stage larvae were now 
seen (Table I ) . These results suggest that each 
anthelmintic interferes with the first moult. 
Effect on viability of S. ratti seocnd-stage larvae. 
A similar protocol was adopted except that 
drug was added 24 hours after incubation. The 
numbers of viable second-stage larvae in each 
group were counted 4 hours later. Thiabenda­
zole and mebendazole had no effect on the via­
bility of second-stage larvae but there was a 
significant (P < 0.005, "t" test) 89% reduction 
in the number of viable second-stage larvae in 
the feces incubated with cambendazole (Ta­
ble I I ) . 
Effect on the second moult of S. ratti 
The same protocol was adopted as in the 
preceding section except that the numbers of 
viable third-stage larvae were counted after 24 
hours incubation with drug (48 hours after 
feces were moistened). No viable infective lar­
vae were seen in feces treated with any of the 
anthelmintics (Table I I ) ; this difference was 
highly significant (P < 0.001, "t" test). These 
results suggest that each anthelmintic interfe­
res with the second moult. 
Effect on viability of S. ratti third stage larvae 
Four petri dishes each containing four 
groups of 4,000 larvae in 4 ml water were incu­
bated with either no drug or 400 Mg of thiaben­
dazole, mebendazole or cambendazole (concen­
tration 100 /ig/ml). The viability of infective lar­
vae was assessed 48 hours later. The anthel­
mintics had no effect on viability, the percen­
tage alive in control, thiabendazole, mebenda­
zole and cambendazole groups being 90%, 94%, 
92% and 90% respectively. 
Effect on infectivHy of S. ratti third stage larvae 
Four petri dishes each containing 10,000 
larvae in 4 ml water were incubated with either 
no drug or 400 n% of thiabendazole, mebendazole 
or cambendazole (concentration 100 /ig/ml) for 
two hours. After washing three times, groups of 
five mice were infected percutaneously with 
2,000 larvae and the numbers of larvae counted 
in the feces six days later. There were on signi­
ficant effects on the excretion of eggs after in­
cubation of infective larvae with thiabendazole 
or mebendazole but no eggs were seen in the 
mice infected with third stage larvae incubated 
with cambendazole (Table I I I ) ; this difference 
was highly significant (P < 0.01, "t" test). 
Effect on isolated parasitic adult female S. ratti 
Forty small petri dishes were each set up 
with approximately 10 worms in 2 ml PBS. To 
each of these was added 1 ml of PBS contain­
ing either no drug or 3 mg of thiabendazole, 
mebendazole or cambendazole (concentration 1 
mg/ml). Ten dishes were in each group. The 
numbers of viable rhabditiform larvae were 
counted after two hours and 24 hours after in­
cubation. The results are shown in Table IV. 
No drug had any effect on the viability of pa­
rasitic female adult worms. The effect of an­
thelmintics on fecundity could not be assessed 
as very few eggs/rhabditiform larvae were re­
leased in vitro. 
Effect on development of S. stercoralis 
Twenty four small watch glasses were set 
up with 1 ml homogenized feces containing 
approximately 100 rhabditiform larvae. To each 
of these was added 2 ml PBS containing either 
no drug or 1200 /ig of thiabendazole, mebenda­
zole or cambendazole giving a final concentra­
tion of 300 jug drug/ml. Six dishes were in each 
group. Development of worms was observed 
over the next seven days. Thousands of infecti­
ve larvae were seen in each of the control dishes 
but all of the dishes containing thiabendazole, 
mebendazole or cambendazole were completely 
devoid of these worms; this difference was 
highly significant (P = 0.001, Fisher's Exact 
Test). 
Effect on infectivity of S. stercoralis third-stage 
larvae 
Larvae were incubated with or without drug 
as described earlier, then groups of five mice 
were infected percutaneously with 1,000 infecti­
ve larvae and the numbers of larvae in the ham­
string muscles were counted seven days later. 
There were no significant effects on the num­
bers of larvae in the muscles after incubation 
of third-stage larvae with thiabendazole or me­
bendazole, but no larvae were seen in mice in­
fected with third-stage larvae incubated with 
cambendazole (Table I I I ) ; this difference was 
significant (P < 0.005, "t" test). 
Effect on isolated free-living adult S. stercoralis 
Four petri dishes each containing 20 adult 
worms in 3 ml water were incubated with either 
no drug or 3 mg of thiabendazole, mebendazo­
le or cambendazole (concentration 1 mg/ml). 
The viability of these worms was assessed 24 
hours later. The anthelmintics had no effect on 
viability, all worms being alive. 
DISCUSSION 
. This study has shown that although there 
are many similarities in the in vitro effects on 
Strongyloides of the three drugs, there are also 
clear differences in activity, with cambendazole 
having the greatest number of actions and 
thiabendazole and mebendazole being less effi­
cacious. Thiabendazole and cambendazole are 
thought to inhibit the fumarate reductase sys­
tem and its associated oxidative phosphoryla­
tion reactions against some nematodes such as 
Haemoncftus contortus , 8< 2 2. Although a similar 
activity could not be demonstrated with me­
bendazole, it was suggested that this may have 
reflected its use as a suspension, the drug being 
poorly absorbedI5. Cambendazole has been ob­
served to have enhanced potency against a num­
ber of nematodes when compared with thia­
bendazole, and this has been ascribed tentative­
ly to an alteration in its mode of metabolism; 
substitution of an acylamino group in the C-5 
position of the benzimidazole molecule pre­
vented inactivatior by metabolic hydroxylation 
reactions12. 
The concentrations of drug tnat we used 
varied between 100 and 1,000 /tg/ml. This range 
was chosen because analysis of previous in vivo 
dose-response experiments in mice9 indicated 
that such concentrations were sufficient to 
achieve a maximal effect on the worms. For 
example, all worms were killed after adminis­
tration of an oral dose of 2 mg mebendazole 
to a 20 g mouse (concentration = 100 /ig/ml 
assuming complete absorption and even distri­
bution of drug). Since absorption of some of 
these drugs is incomplete 1 5 and distribution in 
vivo may be uneven, the in vitro concentrations 
we used are likely to be even greater than those 
pertaining in the tissues around worms in in­
fected animals, thus ensuring that any differ­
ences in the effects of the three anthelmintics 
would be demonstrable All three benzimida­
zole compounds used had no effect on the hatch­
ing of S. ratti eggs, and thiabendazole and me­
bendazole did not impair the viability of rhab­
ditiform larvae. In contrast, cambendazole re­
duced considerably the number of viable rhab­
ditiform larvae after incubation of these orga­
nisms with the drug for some hours. Similar 
effects were seen with second-stage larvae, thus 
implying that cambendazole has a different me­
chanism of action or is dealt with differently 
by the parasite, and is able to interfere with 
essential metabolic process. The failure of cam­
bendazole to have a similar effect on third sta­
ge larvae does not necessarily contradict this 
hypothesis, for infective larvae are a non-feed­
ing stage and therefore differ metabolically 
from larvae in the earlier stages of develop­
ment. Thus, cambendazole could possibly inhi­
bit the processing of ingested nutrients. A si­
milar argument may apply in the case of S. ratti 
parasitic female adult worms. All three drugs 
inhibited markedly the moulting in vitro of S. 
ratti larvae. This is a critical time in the 
worms' existence and it is possible that they 
may then employ specific metabolic pathways 
which render them susceptible to all the an­
thelmintics. 
The relevance of these findings with the S. 
ratti model to the human parasite S. stercora­
lis was confirmed by showing that all three 
drugs inhibited the moulting of S. stercoralis 
larvae. It was not possible, however, to exa­
mine each stage of S. stercoralis separately be­
cause of the complexity of the free-living deve­
lopmental cycle of these worms. As with S. 
ratti adult worms, these drugs had no effect 
on the viability of S. stercoralis free-living male 
and female adult worms. 
While these observations provide a system 
in which the mechanisms of action of these 
benzimidazole compounds could be investigated 
in detail, the findings which have the greatest 
relevance to treatment of infection were pro­
vided by the studies of the infectivity of lar­
vae after in vitro incubation with the drugs. 
When S. ratti infective larvae were incubated 
with thiabendazole and mebendazole, then were 
used to infect mice, there was no effect on the 
development of patent infections, as evidenced 
by the subsequent excretion of rhabditiform 
larvae in the feces. When these larvae were 
incubated with cambendazole, however, the in­
fection was aborted completely. Again, the re­
levance of the finding with S. ratti to S. ster­
coralis infection was confirmed by similar stu­
dies in which S. stercoralis larvae were incu-
bated with the drugs. S. stercoralis does not 
complete its development in mice, but infective 
larvae pass to the muscles and provide a sys-
tem in which the anthelmintic activity of drugs 
against this parasite can be observed9-10; a si-
milar system has also been used to investigate 
the activity of anthelmintics against hookworm 
larvae16. When S. stercoralis larvae which had 
been incubated with thiabendazole or meben-
dazole were used to infect mice, no significant 
reduction in worm numbers in the muscles 
occurred. In contrast, when these larvae were 
incubated with cambendazole, there was a to-
tal abrogation of infection with no larvae being 
detectable. These results confirm earlier in 
vivo studies in which it was shown that when 
administered to infected mice, thiabendazole 
and mebendazole were ineffective but that 
cambendazole was efficacious9. Thus, incuba-
tion with cambendazole but not thiabendazole 
or mebendazole inhibits the ability of infective 
larvae to develop subsequently. The mechanisms 
of this action is uncertain; it could be related 
to the observed capacity of cambendazole to kill 
first- and second-stage larvae, or it might in 
some way block the ability to moult into fourth-
stage larvae subsequently, or it could act in 
both ways. In favour of the first of these pos-
sibilities is the absence of S. stercoralis larvae 
in the muscles of mice, thus suggesting that 
they were killed by the drugs then disposed of 
by the host phagocytic cells. 
This finding has major implications for the 
therapy of human strongyloidiasis. This infec-
tion is unusal among human helminthic infec-
tions in that autoinfection occurs. Thus, at any 
given moment, there are likely to be third-sta-
ge larvae migrating through the tissues as well 
as adult worms being present in the gastroin-
testinal tract. It is not surprising, therefore, 
that many patients treated with thiabendazole 
or mebendazole fail to respond, since their tis-
sue larvae are unlikely to be affected by these 
drugs. On the other hand, it could be anticipa-
ted that cambendazole would be active against 
these tissue forms and thus eradicate infections. 
This is of the utmost importance in strongyloi-
diasis, for unless all the worms are eliminated, 
those remaining can multiply to cause a recur-
rence of symptoms and provide the potential 
for developing overwhelming strongyloidiasis 
should the patient become immunosuppressed. 
Although cambendazole is not licensed for 
human use, or endorsed as such by the manu-
facturers, it has been used apparently success-
fully and without ill-effect in a number of 
South American studies 1,2,12,17,20. These studies 
were limited, however, in that they were short-
term studies and have not evaluated whether 
or not infection was eradicated. This is diffi-
cult to do in the short-term as worms are often 
hard to find prior to treatment, and any par-
tial reduction in worm burden often makes 
them impossible to detect; patients need to be 
followed for months to years in order to allow 
build-up of worms into sufficient numbers to 
permit their detection. The present in vitro 
observations confirm that cambendazole acts 
in a different manner to thiabendazole and 
mebendazole, and reinforces strongly the view 
that this drug is likely to prove the drug of 
choice in this potentially lethal infection, and 
is worthy of greater consideration. 
RESUMO 
Strongyloides ratti e S. stercoralis: efeitos de 
cambendazol, tiabendazol e mebendazol in vitro 
Os efeitos da incubação de três antihelmín-
ticos, tiabendazol, mebendazol e cambendazol 
sobre Strongyloides foram comparados. Ne-
nhuma droga afetou a eclosão dos ovos de S. 
ratti ou a viabilidade de larvas infectantes ou 
vermes adultos parasitários, mas todas as três 
inibiram a formação de larvas de S. ratti. Além 
disso, cambendazol, mas não tiabendazol ou 
mebendazol, diminuiu a viabilidade de larvas 
de primeiro e segundo estágio de S. ratti. As 
três drogas não tiveram efeito sobre vermes 
adultos de vida livre isolados, de S. stercoralis, 
mas todas evitaram o desenvolvimento de lar-
vas rabditiformes de S. stercoralis. Tiabenda 
zol e mebendazol não tiveram efeito sobre a in¬ 
fectividade de larvas infectantes de S. ratti ou 
de S. stercoralis, mas a infecção com esses ver-
mes foi anulada por incubação prévia com cam¬ 
bendazol. Esses resultados indicam que cam-
bendazol age de modo diferente das outras duas 
drogas. Uma vez que ele é ativo contra lar 
vas migrando através dos tecidos, é potencial 
mente de muito maior valor que o tia bendazol 
ou mebendazol na terapêutica da esbrongiloi¬ 
díase. 
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